TABLE 5.
Summary of toxicokinetic studies on TBBPA and TBBPA‐bDiBPrE addressing absorption rate/bioavailability reported in the previous Opinion (EFSA CONTAM Panel, 2011c) and studies identified since then.
| Dose(s) tested | Route of exposure | Absorption rate/bioavailability | Species | Reference |
|---|---|---|---|---|
| TBBPA | ||||
| 2 mg/kg bw of [14C]‐TBBPA | Gavage | 70% a | Cannulated and conventional male Sprague–Dawley rats | Hakk et al. (2000) |
| 2, 20, 200 mg/kg bw [14C]‐TBBPA | Oral/iv | 1.6% b | Male Fischer‐344 rats | Kuester et al. (2007) |
| 25, 250, 1000 mg/kg bw [14C]‐TBBPA | Oral/iv | 4.8% b | Female Wistar Han IGS rats | Knudsen et al. (2014) |
| TBBPA derivatives | ||||
| 20 mg/kg bw of [14C]‐TBBPA‐bDiBPrE | Oral/iv | 2.2% b | Male Fischer‐344 rats | Knudsen et al. (2007) |
Abbreviation: iv, intravenous.
a
These values estimated the % of absorption, based on the recovery rate after single oral exposure only.
b
These values correspond to the bioavailability (comparison oral vs. iv route).